Trial shows trastuzumab should remain as standard of care for HER2-positive breast cancer

(Mayo Clinic) Analysis of more than 8,000 women who participated in the world's largest study of two treatments for HER2-positive breast cancer reinforces other findings from the clinical trial showing that trastuzumab, also known as Herceptin, should remain the standard of care for this cancer, says a Mayo Clinic researcher.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news